

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 infection-fatality ratios, COVID-19 and rheumatic disease, waning effectiveness of vaccine third dose, TGA approval for EVUSHIELD

Peer reviewed journals featured:

- A systematic review on variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era [here](#) and associated commentary [here](#)
- Narrative reviews on:
 - COVID-19 in people with rheumatic diseases [here](#)
 - Ethics of childhood COVID-19 vaccination [here](#)
- An observational study on the association of COVID-19 quarantine duration and post quarantine transmission risk in 4 US universities [here](#)
- Commentary on the UK's COVID-19 data collection [here](#)

Letters and correspondence discussed:

- Myocarditis after Comirnaty (Pfizer) vaccination among adolescents in Hong Kong [here](#)

Pre-peer review articles featured:

- Waning effectiveness of the third dose of the Comirnaty (Pfizer) vaccine [here](#)
- Booster protection against Omicron infection in a highly vaccinated population [here](#)
- Protection by vaccines and previous infection against the Omicron variant [here](#)
- Risk of COVID-19 related deaths for Omicron compared with Delta in the UK [here](#)
- Protection of Omicron sub-lineage infection against reinfection by another Omicron sub-lineage [here](#)
- The impact of COVID passport mandates on COVID-19 cases and hospitalisations in the UK [here](#)
- Duration of protection against SARS-CoV-2 reinfection and associated risk of reinfection [here](#)
- Follow-up investigation and detailed mutational characterisation of the Omicron variant lineages (BA.1, BA.2, BA.3 and BA.1.1) [here](#)
- Impact of Omicron variant on the response to mRNA vaccination in multiple myeloma and monoclonal gammopathies [here](#)

Guidance and reports

- The Therapeutic Goods Administration (TGA) issued provisional approval to the combination therapy (tixagevimab and cilgavimab, EVUSHELD) for pre-exposure prevention of COVID-19 [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The UK Health Security Agency published its latest report on SARS-CoV-2 variants of concern and variants under investigation [here](#)

News and blogs

- Wuhan market was epicentre of pandemic's start [here](#)
- The UK National Audit Office notes success of COVID-19 vaccine program but warns of staff burnout [here](#)
- Had Omicron? You're unlikely to catch its rising variant [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).